Earnings
Johnson & Johnson reported a strong first quarter with $20 billion in sales that was fueled by significant growth in its pharmaceuticals business.
Reinforced cash position finances operations through key clinical milestones to mid-2019, phase IIb clinical programs for ABX464 in HIV and IBD patients expected to be initiated around end of 2018.
Here’s a look at eight biopharma companies with upcoming catalysts.
OPKO Health’s fourth-quarter report highlighted positive activities in the face of a net loss of $213.9 million during the most recent quarter.
It took more than 8 months and a series of sweetened offers, but Sanofi was able to close their $11.6B deal to buy Bioverativ without triggering an auction.
Less than two months into the year, Teva’s new chief has already effectively written off a recovery for 2018.
The company goes “above and beyond” with staggering 7% or greater dividend raises over 25 years.
AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate.
TxCell today reports its fourth quarter 2017 financials and provides an update on its financing.
Entresto, introduced in 2015, got off to a slow start but brought in $507 million in revenue last year.
PRESS RELEASES